Magdalena Jarzabek
Family · Chicago, ILNPI 1093016479
Payments from drug & device makers
Across 119 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$512
- AbbVie$360
- Pfizer$274
- Otsuka America Pharmaceutical, Inc.$268
- Amgen$179
- Lundbeck LLC$139
- plus $828 from 14 others
What the payments were for
- Food & beverage$2,560100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $512 |
| AbbVie | 13 | $360 |
| Pfizer | 15 | $274 |
| Otsuka America Pharmaceutical, Inc. | 8 | $268 |
| Amgen | 9 | $179 |
| Lundbeck LLC | 7 | $139 |
| GSK | 6 | $127 |
| Exact Sciences | 6 | $119 |
| Lilly USA, LLC | 5 | $102 |
| Astellas Pharma US Inc | 4 | $84 |
| Hologic Sales And Service, LLC | 3 | $58 |
| Currax Pharmaceuticals LLC | 4 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $55 |
| Merck | 2 | $48 |
| Cranial Technologies, Inc | 3 | $46 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| Phadia US Inc. | 2 | $32 |
| Alfasigma USA, Inc. | 2 | $29 |
| Redhill Biopharma Inc. | 1 | $16 |
| Avion Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,560 in reported general payments places this provider in the 85th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 25 | $24,443 |
| Atorvastatin Calcium | 67 | $601 |
| Losartan Potassium | 32 | $487 |
| Lisinopril | 34 | $439 |
| Amlodipine Besylate | 52 | $427 |
| Metoprolol Succinate | 28 | $330 |
| Trazodone Hcl | 25 | $313 |
| Gabapentin | 13 | $247 |
| Metformin Hcl | 23 | $227 |
| Hydrochlorothiazide | 21 | $208 |
| Tamsulosin Hcl | 14 | $208 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 35 | $189 |
| Simvastatin | 15 | $161 |
| Fluticasone Propionate | 13 | $158 |
| Alendronate Sodium | 18 | $141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $512 | $24,44325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,941 family providers in Illinois.
Other family in Chicago
- Ruth CarricoChicago$582K
- Jamie BroganChicago$282K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Brittony CroasdellChicago$192K
- Stephanie Bradley-MillerChicago$156K
- Elizabeth LegorretaChicago$150K
- Staci GorsonChicago$61K
- Allison MoserChicago$60K
- Darcie McDonaughChicago$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.